Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR – Get Free Report) Director Yusheng Han bought 5,990 shares of the stock in a transaction on Tuesday, June 23rd. The shares were purchased at an average price of $7.50 per share, with a total value of $44,925.00. Following the acquisition, the director owned 18,129,186 shares in the company, valued at approximately $135,968,895. This represents a 0.03% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Yusheng Han also recently made the following trade(s):
- On Friday, June 26th, Yusheng Han purchased 24,900 shares of Burning Rock Biotech stock. The stock was purchased at an average price of $8.00 per share, for a total transaction of $199,200.00.
- On Wednesday, June 24th, Yusheng Han acquired 250,000 shares of Burning Rock Biotech stock. The shares were purchased at an average cost of $8.00 per share, with a total value of $2,000,000.00.
- On Monday, June 22nd, Yusheng Han acquired 104,650 shares of Burning Rock Biotech stock. The shares were purchased at an average cost of $7.45 per share, with a total value of $779,642.50.
- On Tuesday, June 16th, Yusheng Han acquired 111,110 shares of Burning Rock Biotech stock. The shares were purchased at an average price of $9.00 per share, with a total value of $999,990.00.
- On Friday, June 12th, Yusheng Han bought 210,000 shares of Burning Rock Biotech stock. The stock was purchased at an average cost of $9.25 per share, for a total transaction of $1,942,500.00.
- On Thursday, June 11th, Yusheng Han bought 24,760 shares of Burning Rock Biotech stock. The stock was purchased at an average cost of $8.74 per share, for a total transaction of $216,402.40.
Burning Rock Biotech Stock Performance
NASDAQ BNR opened at $9.82 on Friday. Burning Rock Biotech Limited Sponsored ADR has a 52 week low of $3.23 and a 52 week high of $41.72. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.81 and a current ratio of 3.05. The stock’s 50 day moving average price is $12.35 and its two-hundred day moving average price is $19.96. The stock has a market capitalization of $103.31 million, a price-to-earnings ratio of -11.98 and a beta of 1.32.
Wall Street Analysts Forecast Growth
A number of research firms recently weighed in on BNR. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Burning Rock Biotech in a research report on Monday, April 20th. Wall Street Zen cut shares of Burning Rock Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, June 13th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Burning Rock Biotech currently has an average rating of “Sell”.
Get Our Latest Stock Analysis on Burning Rock Biotech
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the stock. Crcm LP raised its stake in shares of Burning Rock Biotech by 13.8% during the 3rd quarter. Crcm LP now owns 221,575 shares of the company’s stock worth $1,917,000 after purchasing an additional 26,809 shares in the last quarter. Prospera Financial Services Inc grew its stake in shares of Burning Rock Biotech by 26.0% in the fourth quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock valued at $628,000 after buying an additional 6,430 shares in the last quarter. Marshall Wace LLP bought a new position in shares of Burning Rock Biotech in the fourth quarter valued at $220,000. Finally, Renaissance Technologies LLC increased its holdings in Burning Rock Biotech by 13.8% during the first quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock worth $571,000 after buying an additional 4,290 shares during the last quarter. Institutional investors and hedge funds own 30.03% of the company’s stock.
About Burning Rock Biotech
Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.
Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.
Featured Articles
- Five stocks we like better than Burning Rock Biotech
- AST SpaceMobile’s Japan Catalyst Puts Its Rollout Story Back in Focus
- Gold and Silver Recovery—3 Precious Metals Stocks for H2 2026
- Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst
- Why Kroger’s Giant Eagle Deal Could Change Everything
Receive News & Ratings for Burning Rock Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Burning Rock Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
